Traders should monitor for top-line data in Q4 2026, which could serve as a major catalyst. Positive results may lead to partnership interest or accelerated development, potentially re-rating the stock.
Price Chart
Executive Summary
Aclaris Therapeutics announced completion of patient enrollment in its Phase 2 trial of bosakitug (ATI-045), an anti-TSLP monoclonal antibody, for moderate-to-severe atopic dermatitis. Top-line results are expected in Q4 2026, marking a key clinical milestone for the investigational therapy with potential best-in-class properties.
Key Facts
- Completed patient enrollment in a Phase 2 trial of bosakitug for moderate-to-severe atopic dermatitis.
- Trial includes 109 patients; primary endpoint is percent change in EASI score at week 24.
- Top-line results expected in Q4 2026.
- Bosakitug showed strong efficacy in a prior Phase 2a trial: 94% achieved EASI-75 and 88% achieved clear/nearly clear skin (IGA 0/1) at week 26.
- Drug has a 23-day half-life, supporting infrequent dosing, and high potency with low dissociation rate from TSLP.
Financial Impact
No immediate financial impact; potential long-term value creation if trial succeeds. Market cap remains $468M with no near-term revenue expected.
Risk Factors
- Clinical trial results may not replicate prior Phase 2a outcomes.
- Development delays or safety issues could derail progress.
- High biotech risk due to reliance on unproven clinical-stage asset.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3258004 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 8-K | $3.88 | awaiting T+5 | — | $3.79 (+2.32%) |
Oct 27, 2026 today | 424B5 | $3.91 | awaiting T+5 | — | $3.79 (+3.04%) |
Oct 27, 2026 today | 8-K | $3.78 | awaiting T+5 | — | $3.79 (+0.26%) |
Oct 27, 2026 today | Press Release | $3.89 | awaiting T+5 | — | $3.79 (−2.57%) |
Aug 11, 2026 11w ago | Institutional Cluster | $5.84 $6.44 | ▲ +10.27% | ▲ +10.72% | $3.79 (−35.10%) |
Aug 6, 2026 11w ago | 8-K | $6.09 $5.86 | ▼ −3.78% | ▼ −4.99% | $3.79 (−37.77%) |
Apr 28, 2026 26w ago | 8-K | $4.22 $4.75 | ▲ +12.56% | ▲ +10.87% | $3.79 (−10.19%) |
Apr 28, 2026 26w ago | Press Release | $4.22 $4.75 | ▲ +12.56% | ▲ +10.87% | $3.79 (−10.19%) |
Apr 23, 2026 26w ago | DEFA14A | $4.55 $4.47 | ▼ −1.76% | ▼ −3.24% | $3.79 (−16.70%) |
Mar 27, 2026 30w ago | Press Release | $3.52 $3.80 | ▲ +7.95% | ▲ +4.09% | $3.79 (+7.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers